1. Home
  2. BTAI

BTAI

BioXcel Therapeutics Inc.

Logo BioXcel Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-18-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Founded: 2017 Country:
United States
United States
Employees: N/A City: NEW HAVEN
Market Cap: 86.2M IPO Year: 2018
Target Price: $6.17 AVG Volume (30 days): 1.5M
Analyst Decision: Buy Number of Analysts: 8
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -6.15 EPS Growth: N/A
52 Week Low/High: $1.91 - $29.56 Next Earning Date: 05-06-2024
Revenue: $1,380,000 Revenue Growth: 268.00%
Revenue Growth (this year): 163.62% Revenue Growth (next year): 286.42%

Share on Social Networks: